Covalon Technologies Ltd

Wound Care and other Innovative Antimicrobial Technologies

Mississauga, Ontario, Aug. 15, 2012 – Covalon Technologies Ltd. (TSXV: COV), a Canadian ISO 13485:2003 advanced medical technologies company, will make its first appearance at MEDICA the world’s largest medical technology trade fair, November 14 to 17 in Düsseldorf, Germany. As part of its debut, Covalon will be showcasing a suite of advanced bio-active wound care products, clear film antimicrobial surgical wound and IV securement dressings, along with lubricious and antimicrobial coated catheters – all of which are available for distribution internationally.

"We are extremely interested in being at MEDICA this year because we want to share with visitors the great interest in Covalon’s advanced technologies already expressed by clinicians and medical product companies,” says Brian Pedlar, Covalon's Chief Executive Officer. “Covalon is looking forward to establishing working relationships with clinicians and medical companies in Germany, Europe, and the rest of the world.”

Among Covalon breakthroughs to be seen at MEDICA will be SurgiClear™, a new, clear film dressing uniquely designed to reduce the instances of surgical site infections. SurgiClear, with its antimicrobial silicone adhesive technology, is the first transparent film dressing that allows both clinicians and patients to monitor a surgical site’s healing process – while still providing effective antimicrobial protection with both silver and chlorhexidine. For up to seven days, SurgiClear provides an effective barrier to external contamination and inhibits organism growth under the dressing because it has two antimicrobial compounds infused directly into the silicone adhesive.

“We are looking forward to introducing our new line-up of products to our growing domestic and international distribution channels and to medical product companies who are looking to license new breakthrough products," concludes CEO Pedlar.
To learn more about Covalon’s products and services, please visit Covalon at the Ontario Canada Pavilion in booth G42, Hall 16 or contact Brian Pedlar, CEO, Covalon Technologies Ltd. at bpedlar@covalon.com.

About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in speciality areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com. Follow on Twitter @covalon.

Brian Pedlar
CEO, Covalon Technologies Ltd.
E: bpedlar@covalon.com
T: (905) 568-8400 x 233
F: (905) 568-5200

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.